These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16166447)

  • 41. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.
    Zhang R; Tian L; Chen LJ; Xiao F; Hou JM; Zhao X; Li G; Yao B; Wen YJ; Li J; Zhang L; Chen XC; Luo F; Peng F; Jiang Y; Wei YQ
    Gene Ther; 2006 Sep; 13(17):1263-71. PubMed ID: 16672984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
    Shi S; Tao L; Song H; Chen L; Huang G
    APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
    Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
    Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of multidrug transporter in tumor endothelial cells enhances antiangiogenic effects of low-dose metronomic paclitaxel.
    Akiyama K; Maishi N; Ohga N; Hida Y; Ohba Y; Alam MT; Kawamoto T; Ohmura H; Yamada K; Torii C; Shindoh M; Hida K
    Am J Pathol; 2015 Feb; 185(2):572-80. PubMed ID: 25498238
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I; Spugnini EP; Galluzzo P; Contestabile M; Dell'Anna ML; Picardo M; Crispi S; Calogero RA; Piccolo MT; Arigoni M; Cantarella D; Boccellino M; Quagliuolo L; Ferretti G; Carlini P; Felici A; Boccardo F; Cognetti F; Baldi A
    Future Oncol; 2013 Sep; 9(9):1375-88. PubMed ID: 23980684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis.
    Reiner T; de las Pozas A; Gomez LA; Perez-Stable C
    Cancer Lett; 2009 Apr; 276(1):21-31. PubMed ID: 19046802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
    Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
    Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma.
    Levitt JM; Jian W; Lerner SP; Sonpavde G
    Urol Oncol; 2013 Feb; 31(2):234-40. PubMed ID: 21723160
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
    Imai A; Zeitlin BD; Visioli F; Dong Z; Zhang Z; Krishnamurthy S; Light E; Worden F; Wang S; Nör JE
    Cancer Res; 2012 Feb; 72(3):716-25. PubMed ID: 22158856
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
    Shen FZ; Wang J; Liang J; Mu K; Hou JY; Wang YT
    Int J Exp Pathol; 2010 Feb; 91(1):10-6. PubMed ID: 20096070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer.
    Campbell NE; Greenaway J; Henkin J; Moorehead RA; Petrik J
    Neoplasia; 2010 Mar; 12(3):275-83. PubMed ID: 20234821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice.
    Touil YS; Seguin J; Scherman D; Chabot GG
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):445-55. PubMed ID: 21069336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.